SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

06 May 2023 11:30:00 By Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

04 May 2023 16:05:01 By Nasdaq GlobeNewswire

Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

01 May 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

26 Apr 2023 16:05:01 By Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

20 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023

13 Apr 2023 16:05:41 By Nasdaq GlobeNewswire

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

03 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

13 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

09 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

23 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference

22 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

Sight Sciences Announces 1,000th TearCare® Customer Installation

26 Jan 2023 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results

09 Jan 2023 16:20:00 By Nasdaq GlobeNewswire

Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months

08 Dec 2022 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Third Quarter 2022 Financial Results

10 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure

03 Nov 2022 08:30:01 By Nasdaq GlobeNewswire

Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022

20 Oct 2022 17:20:54 By Nasdaq GlobeNewswire

Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

29 Sep 2022 08:30:00 By Nasdaq GlobeNewswire